Compare RAVE & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAVE | PLUR |
|---|---|---|
| Founded | 1958 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.5M | 34.9M |
| IPO Year | N/A | N/A |
| Metric | RAVE | PLUR |
|---|---|---|
| Price | $2.83 | $3.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 63.5K | 57.7K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.08 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $12,202,000.00 | $1,326,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | $14.66 | ★ N/A |
| Revenue Growth | 0.73 | ★ 121.74 |
| 52 Week Low | $2.01 | $3.20 |
| 52 Week High | $3.75 | $7.13 |
| Indicator | RAVE | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 41.43 |
| Support Level | $2.84 | $3.20 |
| Resistance Level | $3.19 | $3.94 |
| Average True Range (ATR) | 0.21 | 0.35 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 9.09 | 13.21 |
Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.